introduction: several lines of evidence suggest that the factor xiii (fxiii) 100 g/t polymorphism may influence susceptibility to deep venous thromboembolism (dvt). to explore this hypothesis, we investigated whether this polymorphism is associated with the predisposition to dvt. we also predict the possible impact of residue substitution at codons 34 (val34leu) in a subunits of the fxiii coagu...

OBJECTIVE Activated factor XIII (FXIII) crosslinks fibrin to enhance the mechanical strength of a blood clot and increase its resistance to fibrinolysis. The prevalence of a common variant in the FXIII-A gene (V34L) has been reported to be lower in patients with myocardial infarction and ischemic stroke than in controls, suggesting a protective role for this polymorphism in vascular diseases. T...

As FXIII-B intron K nt29756 polymorphism and its combination with FXIII-A Val34Leu polymorphism decreased FXIII levels, it was intriguing to find out if decreased FXIII levels were associated with protection against CAD. To address this question, individuals with FXIII levels in the lower tertile were compared to those with FXIII levels in the upper tertile. In the total population, not stratif...

Macular degenerations represent leading causes of central blindness or low vision in developed countries. Most of these severe visual disabilities are due to age-related macular degeneration (AMD) and pathologic myopia (PM), both of which are frequently complicated by subfoveal choroidal neovascularization (CNV). Photodynamic therapy with verteporfin (PDT-V) is still employed for CNV treatment ...

The Val34Leu polymorphism in the A subunit of blood coagulation factor XIII (FXIII-A) is located in the activation peptide, just three amino acids upstream of the thrombin cleavage site. The Val-->Leu replacement accelerates the rate of the proteolytic activation of FXIII and it seems to provide protection against myocardial infarction. Methods available for the assessment of the FXIII-A Val34L...

Although the Val34Leu polymorphism in blood coagulation factor XIII-A (FXIII-A) has been implicated in the pathogenesis of intracerebral hemorrhage (ICH), the results of research conducted thus far have been inconclusive. In this meta-analysis, we have assessed the association between the FXIII-A Val34Leu polymorphism and ICH risk. Published reports pertaining to this association were retrieved...

Although many epidemiologic studies have investigated the FXIII-A Val34Leu polymorphism and their associations with myocardial infarction (MI), definite conclusions can't be drawn. To clarify the effects of FXIII-A Val34Leu polymorphism on the risk of MI, a meta-analysis was performed. Related studies were identified from PubMed, Springer Link, Ovid, Chinese Wanfang Data Knowledge Service Platf...

BACKGROUND AND PURPOSE The identification of genetic and environmental factors that could improve the benefit/risk ratio of thrombolytic therapy in patients with ischemic stroke is crucial. METHODS We studied the role in the efficacy and side-adverse effects of thrombolytic therapy in stroke of 2 factors involved in the structure and stability of fibrin clot: fibrinogen levels and factor XIII...

BACKGROUND The mechanism underlying decreased risk for myocardial infarction in carriers of the Leu34 polymorphism of the factor (F) XIII A-subunit is unclear. Given that acetylation of fibrinogen by aspirin can alter its clotting properties and the presence of fibrin stimulates thrombin-mediated activation of FXIII, we have tested the hypothesis that treatment with aspirin differentially modul...

The polymorphism in the factor XIII A-subunit gene (FXIII Val34Leu) has been recognized as a risk factor for primary intracerebral hemorrhage (PICH). In addition, FXIII Val34Leu has a significant ethnic heterogeneity. FXIII Val34Leu was detected in 41.7-54.8% of the Westerners, but in 2.5% of the Asians. We aimed to evaluate the prevalence of FXIII Val34Leu in patients with PICH and in healthy ...